Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (i.v.) and oral (p.o.) antifungal prodrug candidate is currently in clinical development for the treatment of invasive fungal infections. Manogepix (MGX, APX001A), the active moiety of FMGX, interferes with cell wall synthesis by targeting fungal glycosylphosphatidylinositol-anchored cell wall transfer protein 1, thereby causing loss of cell viability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Manogepix is a preclinical antifungal that blocks GPI anchor biosynthesis in the ER (38), which produces cellular stresses that very strongly activate calcineurin signaling in C. glabrata (36).”
From Echinocandin tolerance and persistence in vitro are regulated by calcineurin signaling in Candida glabrata (2026) · cites this paper as [38]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953
Abraham, J. (2010) · Handbook of Transnational Economic Governance Regimes · doi:10.1163/ej.9789004163300.i-1081.897 · Cited by 2,582
Viswanathan, C. T., Bansal, S., Booth, B., DeStefano, A. J., Rose, M. J., Sailstad, J., Shah, V. P., Skelly, J. P., Swann, P. G., & Weiner, R. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9291-7 · Cited by 826 · cited 1×
“FDA Guidance for Industry-Bioanalytical Method Validation (35), a conference report (36), and the EMA guideline on bioanalytical method validation (37).”
BackgroundInvasive Fungal Pathogens: Current Epidemiological Trends
Pfaller, M. A., Pappas, P. G., & Wingard, J. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504490 · Cited by 448 · cited 3×
“AUC(1), area under the concentration-time curve from time zero to infinity; Cmax, maximum plasma concentration; FMGX, fosmanogepix; IV, intravenous; MGX, manogepix; n, number of participants; PK, pharmacokinetics.”
BackgroundMethodInfluentialEchinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
de Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. D. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01351 · Cited by 350
Prevalence of Immunosuppression Among US Adults, 2013
Harpaz, R., Dahl, R. M., & Dooling, K. L. (2016) · JAMA · doi:10.1001/jama.2016.16477 · Cited by 266
Vallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., Kemble, S. K., Pacilli, M., Black, S. R., Landon, E., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14121 · Cited by 247
Research works printed but not linked: 2
- Watanabe NA, Horii T, Miyazaki M, Hata K. 2011. In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals, abstr F1-1378. Abstr Interscience Conference on Antimicrobial Agents and Chemotherapy, ASM, Chicago, IL.
- Gebremariam T, Alkhazraji S, Alqarihi A, Wiederhold NP, Shaw KJ, Patterson TF, et al. 2017. APX001 protects immunosuppressed mice from Rhizopus delemar infection. Abstr IDweek 2017, San Diego, CA. Poster 1521.
Cited by
Advancements and challenges in antifungal therapeutic development
Puumala, E., Fallah, S., Robbins, N., & Cowen, L. E. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00142-23 · Cited by 140
“Upon oral or intravenous administration, fosmanogepix is metabolized by systemic alkaline phosphatases to its active moiety, manogepix (APX001A, previously E1210) (37).”
BackgroundYuan, Y., Li, P., Li, J., Zhao, Q., Chang, Y., & He, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01759-7 · Cited by 130
New treatment options for critically important WHO fungal priority pathogens
Kriegl, L., Egger, M., Boyer, J., Hoenigl, M., & Krause, R. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.03.006 · Cited by 105
Hodges, M. R., Tawadrous, M., Cornely, O. A., Thompson, G. R., Slavin, M. A., Maertens, J. A., Dadwal, S., Rahav, G., Hazel, S., Almas, M., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf185 · Cited by 52
“…of antifungals, which inhibits fungal glycosylphosphatidylinositol (GPI)-anchored wall transfer protein 1 (Gwt1), an inositol acyl-transferase essential for trafficking and anchoring mannoproteins to the fungal cell membrane and cell wall, critical for host cell invasion and infection [5, 10, 11].”
InfluentialSelf-citationNew antifungal strategies and drug development against WHO critical priority fungal pathogens
Li, Y., Liu, Y., Jiang, Y., Yang, Y., Ni, W., Zhang, W., & Tan, L. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1662442 · Cited by 53
Structural insights into the inhibition mechanism of fungal GWT1 by manogepix
Dai, X., Liu, X., Li, J., Chen, H., Yan, C., Li, Y., Liu, H., Deng, D., & Wang, X. (2024) · Nature Communications · doi:10.1038/s41467-024-53512-x · Cited by 35
Calcineurin-dependent contributions to fitness in the opportunistic pathogen Candida glabrata
Pavesic, M. W., Gale, A. N., Nickels, T. J., Harrington, A. A., Bussey, M., & Cunningham, K. W. (2024) · mSphere · doi:10.1128/msphere.00554-23 · Cited by 22
“Manogepix is an experimental antifungal that blocks an intermediate step in GPI-anchor biosynthesis in the ER encoded by essential GWT1 (41).”
BackgroundAntifungal pipeline: New tools for the treatment of mycoses
Wolfgruber, S., Salmanton‐García, J., Kuate, M. P. N., Hoenigl, M., & Brunelli, J. G. P. (2024) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2024.11.001 · Cited by 31
Molecular basis of the inositol deacylase PGAP1 involved in quality control of GPI-AP biogenesis
Hong, J., Li, T., Chao, Y., Xu, Y., Zhu, Z., Zhou, Z., Gu, W., Qu, Q., & Li, D. (2024) · Nature Communications · doi:10.1038/s41467-023-44568-2 · Cited by 25
Recent Advances in the Development of Antifungal Agents: Beyond Azoles, Polyenes, and Echinocandins
Saini, V., Safwan, S. M., Mehta, D., Das, E. E., & Bajaj, A. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00828 · Cited by 25
Azole-Resistant Aspergillus fumigatus: Epidemiology, Diagnosis, and Treatment Considerations
Zubovskaia, A. (2025) · Journal of Fungi · doi:10.3390/jof11100731 · Cited by 23
“This results in the inability of the fungal cells to adhere to mucosal/epithelial surfaces, eliminating the initial steps of the infectious process [161,164].”
Cornely, O. A., Ostermann, H., Koehler, P. A., Teschner, D., Limburg, E., Kramer, W. G., Barbat, S. H., Tawadrous, M., & Hodges, M. R. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad269 · Cited by 21
Self-citationEspinel‐Ingroff, A., & Wiederhold, N. P. (2024) · Journal of Fungi · doi:10.3390/jof10050362 · Cited by 19
“…Candida infections, considerable bioavailability following oral administration in humans, extensive tissue penetration, and a favorable safety profile, fosmanogepix may become a treatment option in patients with invasive candidiasis, including those with chorioretinitis or meningitis [6,14,17–20].”
BackgroundCurrent Perspectives of Antifungal Therapy: A Special Focus on Candida auris
Arumugam, G., Muthuselvam, M., de Lima, P. M. N., Rajendran, R., & Junqueira, J. C. (2024) · Journal of Fungi · doi:10.3390/jof10060408 · Cited by 22
Douglas, A. P., Lamoth, F., John, T. M., Groll, A. H., Shigle, T. L., Papanicolaou, G. A., Chemaly, R. F., Carpenter, P. A., Dadwal, S., Walsh, T. J., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.01.892 · Cited by 21
Hsu, A. J., Hanisch, B. R., Fisher, B. T., & Huppler, A. R. (2024) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piad115 · Cited by 17
How do I manage refractory invasive pulmonary aspergillosis
Vergidis, P., Sendi, P., Alkhateeb, H. B., & Nguyen, M. H. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.01.015 · Cited by 12
Hodges, M. R., Hazel, S., Kramer, W. G., van Hoogdalem, E., van Marle, S., Tawadrous, M., & Jakate, A. S. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01455-23 · Cited by 13
“In two phase 1 studies of FMGX in healthy volunteers (NCT02956499 and NCT02957929) (9), a maximum intravenous (IV) dose of 600 mg (3-h infusion) and PO dose of 1,000 mg were administered for 14 days.”
BackgroundSelf-citationNew trends in antifungal treatment: What is coming up?
Guinea, J. (2023) · Revista Española de Quimioterapia · doi:10.37201/req/s01.14.2023 · Cited by 15
Rafique, A., Sharmin, S., Raj, A., Mohiuddin, A. L., Mahmud, M. I. A., & Omer, H. B. M. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.103070 · Cited by 18
Qureshi, Z. A., Ghazanfar, H., Altaf, F., Ghazanfar, A., Hasan, K. Z., Kandhi, S., Fortuzi, K., Dileep, A., & Shrivastava, S. (2024) · Cureus · doi:10.7759/cureus.55498 · Cited by 20
“Manogepix has an in vitro and in vivo activity against Cryptococcus , and the effect is synergistic when combined with fluconazole [71].”
BackgroundCurrent Antifungals and the Developing Pipeline
Johnson, M. D., & Moore, W. J. (2025) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.01.001 · Cited by 12
Hodges, M. R., Ople, E., Evans, P., Pantophlet, A. J., Richardson, J. M., Williams, D., Tripathy, S., Tawadrous, M., & Jakate, A. S. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00273-24 · Cited by 11
Self-citationNickels, T. J., Gale, A. N., Harrington, A. A., Timp, W., & Cunningham, K. W. (2024) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkae173 · Cited by 12
An update on newer antifungals
Akinosoglou, K., Papageorgiou, D., Gogos, C. A., & Dimοpoulos, G. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2461566 · Cited by 11
“Additionally, considering the drug’s predictable and consistent pharmacokinetics, high oral bioavailability, and significant central nervous system penetration, it has the potential to serve as a valuable treatment option for patients with life-threatening invasive fungal infections [55].”
Invasive Aspergillosis in the Intensive Care Unit
Zubovskaia, A., & Vázquez, J. A. (2025) · Journal of Fungi · doi:10.3390/jof11010070 · Cited by 14
Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix
August, B., & Kale-Pradhan, P. B. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2926 · Cited by 11
“6,28,54 In phase I trials, adverse events were mostly mild in nature, consisting of nausea, vomiting, an increase in delirium, and an increase in alanine transaminase (ALT).”
BackgroundOvercoming antifungal resistance in Candida albicans via RNA interference: a therapeutic perspective
Mundhe, A. K., & Rajkumari, R. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1675921 · Cited by 8
Exploring therapeutic strategies for candidiasis: From current treatments to future perspectives
Kantroo, H. A., Mubarak, M. M., & Ahmad, Z. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108797 · Cited by 7
New and emerging drugs for the treatment of invasive fungal infections
Maves, R. C., & Fowler, M. N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2568547 · Cited by 5
“Bioavailability of oral fosmanogepix is nearly 100%, with no apparent effect on absorption seen with high-fat or high-calorie meals [47].”
Gawad, M. M. A. E., & Shady, R. M. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10405-4 · Cited by 8
Therapeutic advances in neuroinfectious diseases
Ardakani, R. V., Jia, L., Matthews, E., & Thakur, K. T. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241274246 · Cited by 8
“53,54 Significant progress has been made in clinical trials of FMGX with successful completion of two phase II studies for the treatment of candidemia and invasive candidiasis with treatment success rates over 80%, as defined by clearance of candidemia (NCT03604705, NCT04148287).”
BackgroundHarrington, A. A., Nickels, T. J., & Cunningham, K. W. (2026) · mBio · doi:10.1128/mbio.02546-25 · Cited by 4
Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program
Cohen, S. H., Allyn, P. R., Chow, F. C., Rathe, J., Nanayakkara, D. D., Hutfles, G., Vijayan, T., Smith, E. A., Saling, C. F., Ilges, D., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag271 · Cited by 6
“Fosmanogepix, the parent compound, is rapidly metabolized by systemic phosphatases to the active form, manogepix [9], which inhibits glycosylphosphatidylinositol (GPI)-anchored wall transfer protein (Gwt1), a fungal enzyme that catalyzes the biosynthesis of GPI-anchor proteins essential for fungal…”
InfluentialNew Perspectives on Antimicrobial Agents: Fosmanogepix
Lamoth, F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-26 · Cited by 6
Nzimande, S., Govender, N. P., & Maphanga, T. G. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01104-23 · Cited by 3
How can we optimize antifungal use and stewardship in the treatment of acute leukemia?
Taynton, T., Allsup, D. J., & Barlow, G. D. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2383401 · Cited by 2
“It has in vitro activity against most Candida species including C. auris (except P. kudriavzevii ), Aspergillus spp., Cryptococcus spp., Fusarium spp., and some causes of mucormycosis [55,56].”
Gowtham, L., Meghana, Y., Mannangatty, T., Vasavi, S., Nirmal, J., Bagga, B., Garg, P., Mishra, D., & Roy, S. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.4.49 · Cited by 2
“38 Preclinical toxicology studies further indicated a wide safety margin with minimal systemic toxicity at therapeutic exposures.”
Management of Candida Infections of the Urinary System
Stewart, A. G., & Hammond, S. P. (2026) · Current Fungal Infection Reports · doi:10.1007/s12281-026-00527-0 · Cited by 1
Mitra, S. (2026) · Future Microbiology · doi:10.1080/17460913.2026.2671628 · Cited by 2
Oldham, M. M., Buckendorf, G., Elmitwalli, I., Sparling, D. P., & Tyungu, D. L. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70195 · Cited by 1
Nickels, T. J., Gale, A. N., Harrington, A. A., Timp, W., & Cunningham, K. W. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.02.592251 · Cited by 1
“Myriocin blocks essenQal enzymes in the ER required for sphingolipid biosynthesis while manogepix potently blocks enzymes in the ER required for GPI anchor biosynthesis and is currently being developed as novel broad-spectrum anQfungal (Hodges et al. 2023; Pappas et al. 2023).”
BackgroundManagement of Chronic Pulmonary Aspergillosis
Bongomin, F., Bromley, M., & Armstrong-James, D. P. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-76524-7_17
Cryptococcosis in Non-HIV Immunocompromised Hosts: Epidemiology, Pathogenesis, and Management
Velez-Pintado, M., Martínez, A. G., Morales, O. R. M., Farías, J. R., & Pintado, P. A. M. V. (2025) · Infectious diseases · doi:10.5772/intechopen.1010118 · Cited by 1
Massey, J., Haidar, G., Shields, R. K., & Tyne, D. V. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001214
Advances in cryptococcal infections-associated immunopathology and potential therapeutic strategies
Павловна, С. Н., Saha, S., Gurina, R., Kuznetsova, O., Zhabo, N., Avdonina, M., & Pilshchikova, O. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1776489
Anti-infective therapy and novel treatment options for coccidioidomycosis
Kuo, A. P., Hamdan, S., Donnelley, M., & Thompson, G. R. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2693682 · Cited by 1
Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives
Al‐Zoubi, R. M., Farhan, A., Hanbali, B., Al-Zoubi, S. R., Al-Zoubi, Y. R., Shkoor, M., Alkharraz, L. M., Agouni, A., & Al-Jabiry, A. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119194
Novel Therapeutics and Antifungal Agents
Anil, A., Chakrabarti, A., & Rudramurthy, S. M. (2026) · Microbiology & infectious diseases : · doi:10.33590/microbiolinfectdisam/462kwc92
Bratosin, F., Bogdan, I. G., & Pescariu, S. A. (2026) · Journal of Fungi · doi:10.3390/jof12100733
“The prodrug has high oral bioavailability, a long half-life and wide tissue distribution [13–15].”
Liu, J., Yang, Y., Tan, Y., Hua, Z., Hu, X., Ding, X., Yang, P., Ke, Y., Zhang, Z., Li, T., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2617140123
The Antifungal Pipeline: New and Future Antifungals
Hendrix, C., Blum, S., Zuniga-Moya, J. C., Spec, A., & Rauseo, A. M. (2026) · Current Clinical Microbiology Reports · doi:10.1007/s40588-026-00280-5
“Phase 1 trials have been completed which established dose range and safety profile with low propensity for CYP3A4 inhibition [61, 62].”
Metadata
- Authors
- Hodges, M. R., Ople, E., Wedel, P., Shaw, K. J., Jakate, A., Kramer, W. G., Marle, S. V., van Hoogdalem, E.-J., & Tawadrous, M.
- Affiliations
- Amplyx Pharmaceuticals (United States) (US)
- Hearts Consulting Group, LLC, Poway, California, USA
- Pfizer (United States) (US)
- Kramer Consulting, LLC, North Potomac, Maryland, USA
- ICON, Groningen, the Netherlands
- Corresponding author
- Hodges, Michael R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2023-04-18
- Volume
- 67
- Issue
- 4
- Pages
- e0162322-e0162322
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC10112065
- OpenAlex
- W4361301291
- Cited by
- 52
- References
- 32
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 20 · 2023: 3
- FWCI
- 10.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Amplyx
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- fosmanogepix, manogepix, pharmacokinetics, drug safety, invasive fungal infections, fungal cell wall biosynthesis, GPI-anchored proteins, healthy volunteers
- MeSH terms
- Invasive Fungal Infections, Adult, Aminopyridines, Antifungal Agents, Biological Availability, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Isoxazoles, Area Under Curve, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.